Engineering Papers⌕ Search

SEARCH · Engineering Papers

Results for “Phase III”

Search indexed NASA NTRS and DOE OSTI research on propulsion, heat transfer, battery materials and energy systems. Follow report and document links to the original sources.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 325 records · Page 18
All sourcesNASA NTRSDOE OSTI
DOE OSTI2020

Iodine Immobilization by Materials through Sorption and Redox-Driven Processes: A Literature Review

Radioiodine-129 (129I) in the subsurface is mobile and limited information is available on treatment technologies. Scientific literature was reviewed to compile information on materials that could potentially be used to immobilize 129I through sorption and redox-driven processes, with an emphasis on ex-situ processes. Candidate materials to immobilize 129I include iron minerals, sulfur-based materials, silver-based materials, bismuth-based materials, ion exchange resins, activated carbon, modified clays, and tailored materials (metal organic frameworks (MOFS), layered double hydroxides (LDHs) and aerogels). Where available, compiled information includes material performance in terms of (i) capacity for 129I uptake; (ii) long-term performance (i.e., solubility of a precipitated phase); (iii) technology maturity; (iv) cost; (v) available quantity; (vi) environmental impact; (vii) ability to emplace the technology for in situ use at the field-scale; and (viii) ex situ treatment (for media extracted from the subsurface or secondary waste streams). Because it can be difficult to compare materials due to differences in experimental conditions applied in the literature, Part II of this review describes results of laboratory studies for selected materials using a standardized batch loading test.

Moore, Robert C.↗
DOE OSTI2022

Machine-learning from Pseudomonas putida KT2440 transcriptomes reveals its transcriptional regulatory network

Bacterial gene expression is orchestrated by numerous transcription factors (TFs). Elucidating how gene expression is regulated is fundamental to understanding bacterial physiology and engineering it for practical use. In this study, a machine-learning approach was applied to uncover the genome-scale transcriptional regulatory network (TRN) in Pseudomonas putida KT2440, an important organism for bioproduction. We performed independent component analysis of a compendium of 321 high-quality gene expression profiles, which were previously published or newly generated in this study. We identified 84 groups of independently modulated genes (iModulons) that explain 75.7% of the total variance in the compendium. With these iModulons, we (i) expand our understanding of the regulatory functions of 39 iModulon associated TFs (e.g., HexR, Zur) by systematic comparison with 1993 previously reported TF-gene interactions; (ii) outline transcriptional changes after the transition from the exponential growth to stationary phases; (iii) capture group of genes required for utilizing diverse carbon sources and increased stationary response with slower growth rates; (iv) unveil multiple evolutionary strategies of transcriptome reallocation to achieve fast growth rates; and (v) define an osmotic stimulon, which includes the Type VI secretion system, as coordination of multiple iModulon activity changes. Taken together, this study provides the first quantitative genome-scale TRN for P. putida KT2440 and a basis for a comprehensive understanding of its complex transcriptome changes in a variety of physiological states.

09 BIOMASS FUELS↗
DOE OSTI2017

Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529

The HIV-1 envelope (Env) spike is a conformational machine that transitions between prefusion (closed, CD4- and CCR5-bound) and postfusion states to facilitate HIV-1 entry into cells. Although the prefusion closed conformation is a potential target for inhibition, development of small-molecule leads has been stymied by difficulties in obtaining structural information. In this paper, we report crystal structures at 3.8-Å resolution of an HIV-1-Env trimer with BMS-378806 and a derivative BMS-626529 for which a prodrug version is currently in Phase III clinical trials. Both lead candidates recognized an induced binding pocket that was mostly excluded from solvent and comprised of Env elements from a conserved helix and the β20–21 hairpin. In both structures, the β20–21 region assumed a conformation distinct from prefusion-closed and CD4-bound states. Together with biophysical and antigenicity characterizations, the structures illuminate the allosteric and competitive mechanisms by which these small-molecule leads inhibit CD4-induced structural changes in Env.

59 BASIC BIOLOGICAL SCIENCES↗
DOE OSTI2019

Lattice engineering enables definition of molecular features allowing for potent small-molecule inhibition of HIV-1 entry

Diverse entry inhibitors targeting the gp120 subunit of the HIV-1 envelope (Env) trimer have been developed including BMS-626529, also called temsavir, a prodrug version of which is currently in phase III clinical trials. Here we report the characterization of a panel of small molecule inhibitors including BMS-818251, which we show to be >10-fold more potent than temsavir on a cross-clade panel of 208-HIV-1 strains, as well as the engineering of a crystal lattice to enable structure determination of the interaction between these inhibitors and the HIV-1 Env trimer at higher resolution. By altering crystallization lattice chaperones, we identify a lattice with both improved diffraction and robust co-crystallization of HIV-1 Env trimers from different clades complexed to entry inhibitors with a range of binding affinities. The improved diffraction reveals BMS-818251 to utilize functional groups that interact with gp120 residues from the conserved β20-β21 hairpin to improve potency.

60 APPLIED LIFE SCIENCES↗
DOE OSTI2015

Quest for the lowest-energy neutrinos in Super-Kamiokande

Super-Kamiokande (SK) has been observing {sup 8}B solar neutrinos for 17 years. Since the start of the SK-III phase, much effort has been expended in reducing backgrounds. The main contributing background comes from the beta decay of {sup 214}Bi, which is produced in the decays of radon in the purified air, detector materials, and the purified water. To reduce this background, the water system of SK has been upgraded. Heat exchangers for the cooling supply water were improved so as to suppress convection in the tank that transports radon near the photomultiplier tubes into the fiducial volume. To evaluate the remaining radon concentration, very-low-background radon detectors for air and water were designed and developed. Not only radon, but other contaminants in the water (bacteria and metal ions) were also investigated.

54 ENVIRONMENTAL SCIENCES↗
DOE OSTI2022

EAST steady-state long pulse H-mode with core-edge integration for CFETR

Recent EAST experiment has successfully demonstrated long pulse steady-state high plasma performance scenario and core-edge integration since the last IAEA in 2018. A discharge with a duration over 60s with β P ~2.0, β N ~1.6, H 98y2 ~1.3 and internal transport barrier on electron temperature channel is obtained with multi-RF power heating and current drive. A higher β N (β N ~1.8, β p ~2.0, H 98y2 ~1.3, n e /n GW ~0.75) with a duration of 20s is achieved by using the modulated neutral beam and multi-RF power, where several normalized parameters are close or even higher than the phase III 1GW scenario of CFETR steady-state. High-Z impurity accumulation in the plasma core is well controlled in a low level by using the on-axis ECH. Modelling shows that the strong diffusion of TEM turbulence in the central region prevents tungsten impurity to accumulate. More recently, EAST has demonstrated compatible core-edge integration discharges in the high βp scenario: high confinement H 98y2 >1.2 with high β P ~2.5/β N ~2.0 and f bs ~50% is sustained with reduced divertor heat flux at high density n e /n GW ~0.7 and moderate q 95 ~6.7. By combining active impurity seeding through radiative divertor feedback control and strike point splitting induced by resonant perturbation coil, the peak heat flux is reduced by 20-30% on the ITER-like tungsten divertor, here a mixture of 50% neon and 50% D2 is applied.

70 PLASMA PHYSICS AND FUSION TECHNOLOGY↗
DOE OSTI2025

Metallothionein expression in Eastern mosquitofish ( Gambusia holbrooki ) exposed to 137 Cs and lead: implications for using metallothionein as a metal exposure biomarker

Given the range of threats facing aquatic ecosystems, it is critical we have monitoring tools to quickly and efficiently identify stressors within ecosystems. Metallothionein’s (MTs) are a group of proteins widely used as biomarkers of metal exposure; however, their suitability has been questioned due to their influenceable nature and ability to be induced by various stressors. Through our study, we sought to (1) evaluate induction of MT in eastern mosquitofish (Gambusia holbrooki) exposed to a radionuclide ( 137 Cs) and metal (Pb), (2) assess the influence of in situ 137 Cs pre-exposure on Pb-induced MT expression, and (3) quantify changes in MT concentrations during Pb depuration. We conducted our experiment in three phases using mosquitofish as a model species: Phase I—pre-exposure to 137 Cs in the field, Phase II—exposure to Pb in the lab immediately following 137 Cs exposure, and Phase III—depuration in the laboratory. We quantified MT concentrations over time and assessed differences among treatments. We did not find in situ exposure of mosquitofish to 137 Cs to induce MT, nor did pre-exposure to 137 Cs appear to influence induction of MT following Pb exposure. Metallothionein was rapidly induced in mosquitofish following Pb exposure; however, MT induction was also observed in control fish. Additionally, there was no apparent relationship between MT and Pb body burdens. During depuration, we found MT concentrations to be highly variable among fish demonstrating no clear response. Furthermore, our study demonstrates the high variability exhibited by MT, the need for further validation of MT as a metal exposure biomarker, and the value in additional research on these proteins under varying exposure scenarios, particularly environmentally realistic concentrations.

54 ENVIRONMENTAL SCIENCES↗
DOE OSTI2023

Continuous cultivation of the lithoautotrophic nitrate‐reducing Fe( II )‐oxidizing culture KS in a chemostat bioreactor

Abstract Laboratory‐based studies on microbial Fe(II) oxidation are commonly performed for 5–10 days in small volumes with high substrate concentrations, resulting in geochemical gradients and volumetric effects caused by sampling. We used a chemostat to enable uninterrupted supply of medium and investigated autotrophic nitrate‐reducing Fe(II)‐oxidizing culture KS for 24 days. We analysed Fe‐ and N‐speciation, cell‐mineral associations, and the identity of minerals. Results were compared to batch systems (50 and 700 mL—static/shaken). The Fe(II) oxidation rate was highest in the chemostat with 7.57 mM Fe(II) d −1 , while the extent of oxidation was similar to the other experimental setups (average oxidation of 92% of all Fe(II)). Short‐range ordered Fe(III) phases, presumably ferrihydrite, precipitated and later goethite was detected in the chemostat. The 1 mM solid phase Fe(II) remained in the chemostat, up to 15 μM of reactive nitrite was measured, and 42% of visualized cells were partially or completely mineral‐encrusted, likely caused by abiotic oxidation of Fe(II) by nitrite. Despite (partial) encrustation, cells were still viable. Our results show that even with similar oxidation rates as in batch cultures, cultivating Fe(II)‐oxidizing microorganisms under continuous conditions reveals the importance of reactive nitrogen intermediates on Fe(II) oxidation, mineral formation and cell–mineral interactions.

59 BASIC BIOLOGICAL SCIENCES↗
DOE OSTI2015

SU-E-T-578: On Definition of Minimum and Maximum Dose for Target Volume

Purpose: This study aims to investigate the impact of different minimum and maximum dose definitions in radiotherapy treatment plan quality evaluation criteria by using tumor control probability (TCP) models. Methods: Dosimetric criteria used in RTOG 1308 protocol are used in the investigation. RTOG 1308 is a phase III randomized trial comparing overall survival after photon versus proton chemoradiotherapy for inoperable stage II-IIIB NSCLC. The prescription dose for planning target volume (PTV) is 70Gy. Maximum dose (Dmax) should not exceed 84Gy and minimum dose (Dmin) should not go below 59.5Gy in order for the plan to be “per protocol” (satisfactory).A mathematical model that simulates the characteristics of PTV dose volume histogram (DVH) curve with normalized volume is built. The Dmax and Dmin are noted as percentage volumes Dη% and D(100-δ)%, with η and d ranging from 0 to 3.5. The model includes three straight line sections and goes through four points: D95%= 70Gy, Dη%= 84Gy, D(100-δ)%= 59.5 Gy, and D100%= 0Gy. For each set of η and δ, the TCP value is calculated using the inhomogeneously irradiated tumor logistic model with D50= 74.5Gy and γ50=3.52. Results: TCP varies within 0.9% with η; and δ values between 0 and 1. With η and η varies between 0 and 2, TCP change was up to 2.4%. With η and δ variations from 0 to 3.5, maximum of 8.3% TCP difference is seen. Conclusion: When defined maximum and minimum volume varied more than 2%, significant TCP variations were seen. It is recommended less than 2% volume used in definition of Dmax or Dmin for target dosimetric evaluation criteria. This project was supported by NIH grants U10CA180868, U10CA180822, U24CA180803, U24CA12014 and PA CURE Grant.

61 RADIATION PROTECTION AND DOSIMETRY↗
DOE OSTI2016

Guidelines by the AAPM and GEC-ESTRO on the use of innovative brachytherapy devices and applications: Report of Task Group 167

Although a multicenter, Phase III, prospective, randomized trial is the gold standard for evidence-based medicine, it is rarely used in the evaluation of innovative devices because of many practical and ethical reasons. It is usually sufficient to compare the dose distributions and dose rates for determining the equivalence of the innovative treatment modality to an existing one. Thus, quantitative evaluation of the dosimetric characteristics of innovative radiotherapy devices or applications is a critical part in which physicists should be actively involved. The physicist’s role, along with physician colleagues, in this process is highlighted for innovative brachytherapy devices and applications and includes evaluation of (1) dosimetric considerations for clinical implementation (including calibrations, dose calculations, and radiobiological aspects) to comply with existing societal dosimetric prerequisites for sources in routine clinical use, (2) risks and benefits from a regulatory and safety perspective, and (3) resource assessment and preparedness. Further, it is suggested that any developed calibration methods be traceable to a primary standards dosimetry laboratory (PSDL) such as the National Institute of Standards and Technology in the U.S. or to other PSDLs located elsewhere such as in Europe. Clinical users should follow standards as approved by their country’s regulatory agencies that approved such a brachytherapy device. Integration of this system into the medical source calibration infrastructure of secondary standard dosimetry laboratories such as the Accredited Dosimetry Calibration Laboratories in the U.S. is encouraged before a source is introduced into widespread routine clinical use. The American Association of Physicists in Medicine and the Groupe Européen de Curiethérapie-European Society for Radiotherapy and Oncology (GEC-ESTRO) have developed guidelines for the safe and consistent application of brachytherapy using innovative devices and applications. The current report covers regulatory approvals, calibration, dose calculations, radiobiological issues, and overall safety concerns that should be addressed during the commissioning stage preceding clinical use. These guidelines are based on review of requirements of the U.S. Nuclear Regulatory Commission, U.S. Department of Transportation, International Electrotechnical Commission Medical Electrical Equipment Standard 60601, U.S. Food and Drug Administration, European Commission for CE Marking (Conformité Européenne), and institutional review boards and radiation safety committees.

60 APPLIED LIFE SCIENCES↗
DOE OSTI2016

MO-A-BRC-02: TG167 Report - Detailed Description

Although a multicenter, Phase III, prospective, randomized trial is the gold standard for evidence-based medicine, it is rarely used to evaluate innovative radiotherapy devices because of many practical and ethical reasons. It is usually sufficient to compare the dose distributions and dose rates for determining equivalence of the innovative device to an existing one. Thus, quantitative evaluation of the dosimetric characteristics of an innovative brachytherapy device or application is a critical part in which physicists are actively involved. The physicist’s role, along with physician colleagues, in this process is highlighted for innovative products or applications and includes evaluation of 1) dosimetric considerations for clinical implementation (including calibrations, dose calculations, and radiobiological aspects) to comply with existing societal dosimetric prerequisites for sources in routine clinical use, 2) risks and benefits from regulatory and safety perspectives, and 3) resource assessment and preparedness. Further, calibration methods should be traceable to a primary standards dosimetry laboratory such as NIST in the U.S. or to other primary standards dosimetry laboratory located elsewhere. Clinical users should follow standards as approved by their country’s regulatory agencies that approved such a brachytherapy device. Integration of this system into the medical source calibration infrastructure of secondary standard dosimetry laboratories such as the ADCLs is encouraged before a source is introduced into widespread routine clinical use. The AAPM and GEC-ESTRO have developed guidelines for the safe and consistent application of brachytherapy using innovative brachytherapy devices and applications. The current report covers regulatory approvals, calibration, dose calculations, radiobiological issues, and overall safety concerns that should be addressed during the commissioning stage preceding clinical use. These guidelines are based on review of requirements of the U.S. NRC, FDA, Department of Transportation, International Electrotechnical Commission Medical Electrical Equipment Standard 60601, European Commission for CE Marking, and institutional review boards and radiation safety committees. Learning Objectives: Understand the necessary dosimetric considerations for clinical implementation (including calibrations, dose calculations, and radiobiological aspects) to comply with existing societal dosimetric prerequisites for sources in routine clinical use. Evaluate risks and benefits from regulatory and safety perspectives. Identify necessary resources and create a plan for clinical introduction of innovative brachytherapy device or applications. Consultant for Theragenics Corp.; R. Nath, Consultant to Theragenics Corp.

60 APPLIED LIFE SCIENCES↗
DOE OSTI2016

MO-A-BRC-00: TG167: Clinical Recommendations for Innovative Brachytherapy Devices and Applicators

Although a multicenter, Phase III, prospective, randomized trial is the gold standard for evidence-based medicine, it is rarely used to evaluate innovative radiotherapy devices because of many practical and ethical reasons. It is usually sufficient to compare the dose distributions and dose rates for determining equivalence of the innovative device to an existing one. Thus, quantitative evaluation of the dosimetric characteristics of an innovative brachytherapy device or application is a critical part in which physicists are actively involved. The physicist’s role, along with physician colleagues, in this process is highlighted for innovative products or applications and includes evaluation of 1) dosimetric considerations for clinical implementation (including calibrations, dose calculations, and radiobiological aspects) to comply with existing societal dosimetric prerequisites for sources in routine clinical use, 2) risks and benefits from regulatory and safety perspectives, and 3) resource assessment and preparedness. Further, calibration methods should be traceable to a primary standards dosimetry laboratory such as NIST in the U.S. or to other primary standards dosimetry laboratory located elsewhere. Clinical users should follow standards as approved by their country’s regulatory agencies that approved such a brachytherapy device. Integration of this system into the medical source calibration infrastructure of secondary standard dosimetry laboratories such as the ADCLs is encouraged before a source is introduced into widespread routine clinical use. The AAPM and GEC-ESTRO have developed guidelines for the safe and consistent application of brachytherapy using innovative brachytherapy devices and applications. The current report covers regulatory approvals, calibration, dose calculations, radiobiological issues, and overall safety concerns that should be addressed during the commissioning stage preceding clinical use. These guidelines are based on review of requirements of the U.S. NRC, FDA, Department of Transportation, International Electrotechnical Commission Medical Electrical Equipment Standard 60601, European Commission for CE Marking, and institutional review boards and radiation safety committees. Learning Objectives: Understand the necessary dosimetric considerations for clinical implementation (including calibrations, dose calculations, and radiobiological aspects) to comply with existing societal dosimetric prerequisites for sources in routine clinical use. Evaluate risks and benefits from regulatory and safety perspectives. Identify necessary resources and create a plan for clinical introduction of innovative brachytherapy device or applications. Consultant for Theragenics Corp.; R. Nath, Consultant to Theragenics Corp.

60 APPLIED LIFE SCIENCES↗
DOE OSTI2016

MO-A-BRC-01: TG167 Report - Introduction

Although a multicenter, Phase III, prospective, randomized trial is the gold standard for evidence-based medicine, it is rarely used to evaluate innovative radiotherapy devices because of many practical and ethical reasons. It is usually sufficient to compare the dose distributions and dose rates for determining equivalence of the innovative device to an existing one. Thus, quantitative evaluation of the dosimetric characteristics of an innovative brachytherapy device or application is a critical part in which physicists are actively involved. The physicist’s role, along with physician colleagues, in this process is highlighted for innovative products or applications and includes evaluation of 1) dosimetric considerations for clinical implementation (including calibrations, dose calculations, and radiobiological aspects) to comply with existing societal dosimetric prerequisites for sources in routine clinical use, 2) risks and benefits from regulatory and safety perspectives, and 3) resource assessment and preparedness. Further, calibration methods should be traceable to a primary standards dosimetry laboratory such as NIST in the U.S. or to other primary standards dosimetry laboratory located elsewhere. Clinical users should follow standards as approved by their country’s regulatory agencies that approved such a brachytherapy device. Integration of this system into the medical source calibration infrastructure of secondary standard dosimetry laboratories such as the ADCLs is encouraged before a source is introduced into widespread routine clinical use. The AAPM and GEC-ESTRO have developed guidelines for the safe and consistent application of brachytherapy using innovative brachytherapy devices and applications. The current report covers regulatory approvals, calibration, dose calculations, radiobiological issues, and overall safety concerns that should be addressed during the commissioning stage preceding clinical use. These guidelines are based on review of requirements of the U.S. NRC, FDA, Department of Transportation, International Electrotechnical Commission Medical Electrical Equipment Standard 60601, European Commission for CE Marking, and institutional review boards and radiation safety committees. Learning Objectives: Understand the necessary dosimetric considerations for clinical implementation (including calibrations, dose calculations, and radiobiological aspects) to comply with existing societal dosimetric prerequisites for sources in routine clinical use. Evaluate risks and benefits from regulatory and safety perspectives. Identify necessary resources and create a plan for clinical introduction of innovative brachytherapy device or applications. Consultant for Theragenics Corp.; R. Nath, Consultant to Theragenics Corp.

60 APPLIED LIFE SCIENCES↗
DOE OSTI2018

Can the Impact of Aerosols on Deep Convection be Isolated from Meteorological Effects in Atmospheric Observations?

Influence of pollution on dynamics of deep convection continues to be a controversial topic. Arguably, only carefully designed numerical simulations can clearly separate the impact of aerosols from the effects of meteorological factors that affect moist convection. This paper argues that such a separation is virtually impossible using observations because of the insufficient accuracy of atmospheric measurements and the fundamental nature of the interaction between deep convection and its environment. To support this conjecture, results from numerical simulations are presented that apply modeling methodology previously developed by the author. The simulations consider small modifications, difficult to detect in observations, of the initial sounding, surface fluxes, and large-scale forcing tendencies. All these represent variations of meteorological conditions that affect deep convective dynamics independently of aerosols. The setup follows the case of daytime convective development over land based on observations during the Large-Scale Biosphere–Atmosphere (LBA) field project in Amazonia. The simulated observable macroscopic changes of convection, such as the surface precipitation and upper-tropospheric cloudiness, are similar to or larger than those resulting from changes of cloud condensation nuclei from pristine to polluted conditions studied previously using the same modeling case. Observations from Phase III of the Global Atmospheric Research Program Atlantic Tropical Experiment (GATE) are also used to support the argument concerning the impact of the large-scale forcing. The simulations suggest that the aerosol impacts on dynamics of deep convection cannot be isolated from meteorological effects, at least for the daytime development of unorganized deep convection considered in this study.

37 INORGANIC, ORGANIC, PHYSICAL, AND ANALYTICAL CH↗
DOE OSTI2022

Induced seismicity potential based on probabilistic geomechanics for the San Juan Basin CarbonSAFE project

Although geologic carbon sequestration projects have yet to induce — or may never induce — a damaging earthquake, experiences from other deep injection industries such as hydraulic fracturing, enhanced geothermal systems, and saltwater disposal suggest that effective quantitative seismic risk assessment is necessary for deep saline carbon capture and sequestration (CCS) projects. One such imminent CCS project is the San Juan Basin CarbonSAFE Phase III program. We use Monte Carlo probabilistic geomechanical analyses combined with observations of the geologic and operational parameters of the San Juan Basin site and suggest that this project is of low-induced seismic risk. The primary analysis is split into four sections. First, we assess the literature for faults and past seismicity, and at least five faulting scenarios are directly relevant. Second, we develop and calibrate an integrated earth model for the project site. Third, we perform Monte Carlo simulations that consider reasonable uncertainties of the geomechanical parameters. Of five tested faulting scenarios, only one presents high Coulomb failure functions, but fourth, we determine the risk to be low based on the combined lack of historical seismicity, the geologic framework of the faulting scenario, and the presence of saltwater injection at the same depth as the proposed supercritical carbon dioxide injection. The most sensitive parameters in the geomechanical calculations are the fault dip and the coefficient of friction. The least sensitive are the fault strike and the orientation of the maximum horizontal principal stress.

58 GEOSCIENCES↗
DOE OSTI2018

SECARB 3D VSP Data

Vertical Seismic Profile data collected in 2009 and 2010 as part of SECARB Phase III Early Test at Cranfield oilfield in Mississippi to determine CO2 induced change from seismic response. Data divided into 3D VSP and Offset VSP folders. Associated Publications: Daley, T. M., Hendrickson, J., & Queen, J. H. (2014). Monitoring CO2 Storage at Cranfield, Mississippi with Time-Lapse Offset VSP – Using Integration and Modeling to Reduce Uncertainty. Energy Procedia, 63, 4240-4248. doi:10.1016/j.egypro.2014.11.459

3D VSP↗
DOE OSTI2020

Integrated Monitoring Volume: A Summary of Monitoring Studies Conducted in Niagaran Carbonate Pinnacle Reefs During Enhanced Oil Recovery with CO2

This introductory report to the Integrated Monitoring Volume provides an executive summary style overview of each of the monitoring methods deployed during the MRCSP Phase III Program. Each method is discussed in detail in a separate report that together with this Executive Summary comprise the Integrated Monitoring Volume.

BHG,DAS,Monitoring,PNC,VSP,borehole gravity,distri↗